News

The U.S. Food and Drug Administration (FDA) has granted fast-track designation to Ouro Medicines’ experimental treatment gamgertamig for autoimmune hemolytic anemia (AIHA), a group of autoimmune diseases that includes cold agglutinin disease. Fast-track designation is intended to accelerate the development and review of potential treatments for serious diseases…

People with cold agglutinin disease (CAD) treated long-term with Enjaymo (sutimlimab-jome) maintained stable hemoglobin levels, avoided blood transfusions, and showed sustained reductions in red blood cell destruction for nearly two years, according to a real-world, single-center study from Germany. “The present small, [single-center]…

A man and a woman in China were found to have a type of fast-growing blood cancer called diffuse large B-cell lymphoma (DLBCL) as the underlying cause of their autoimmune hemolytic anemia (AIHA), a group of disorders in which the immune system attacks and destroys red blood cells, according to…

A short course of rituximab, combined with chemotherapy agents and corticosteroids, can keep primary cold agglutinin disease (CAD) under control for many years, at a lower cost and with manageable side effects, according to a study of seven patients in Japan. “Rituximab-based chemoimmunotherapy elicited durable responses with an…

A combination of chemotherapy and immune-targeting medications may provide long-lasting relief for people with cold agglutinin disease (CAD), though the treatment often comes with a high risk of serious side effects, according to real-world patient data. These “immunochemotherapy” (ICT) regimens, specifically those using R-bendamustine, have shown significant success in normalizing…

The oral medication iptacopan — approved for certain blood and complement-related conditions — helped alleviate anemia in most people with cold agglutinin disease (CAD) in a small Phase 2 clinical trial, according to study. The complement cascade is a component of the immune system that contributes to the hemolysis,…

Enjaymo (sutimlimab-jome) remains safe to use over the long term, according to new real-world data from adults with primary or secondary cold agglutinin disease (CAD) who have been taking the approved medication for an average of more than two years. The data come from CADENCE (NCT05791708), an…

A bacterial lung infection caused by Mycoplasma pneumoniae— a very small cell bacterium known as M. pneumoniae for short — triggered cold agglutinin disease (CAD) and severe blood clotting in a man in his late 50s, according to a case report from the U.S. The man recovered after treatment…

A woman with hard-to-treat cold agglutinin disease (CAD) was later found to have high-grade gastric B-cell lymphoma — a type of blood cancer that originates in the stomach — and treating that cancer was key to controlling her CAD symptoms, a case report shows. The lymphoma, which turned out…

A proof-of-concept study designed to test a new tablet formulation of the experimental therapy ANX1502 in people with cold agglutinin disease (CAD) is continuing dosing to provide further insights into the therapy’s pharmacological profile and its impact on disease biomarkers. Data so far have been promising, showing that blood…